| Project/Area Number |
26560447
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Chemical biology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Fukase Koichi 大阪大学, 理学(系)研究科(研究院), 教授 (80192722)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MANABE Yoshiyuki 大阪大学, 大学院理学研究科, 助教 (00632093)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | がん免疫療法 / 抗体薬物複合体（ADC） / 糖鎖 / 糖鎖合成 / α-gal / がんワクチン / アジュバント / 免疫療法 / α-Gal / グリコシル化 |
|---|
| Outline of Final Research Achievements |
The α-Gal epitope is composed of trisaccharide structure produced in most mammals, however humans are deficient in that structure. On the other hand, humans produce a large amount of anti-Gal antibodies that specifically interact with the α-Gal epitope. Therefore, if pig organ expressing α-Gal is transplanted to human, the organ is heavily injured by hyper acute rejection. The purpose of this research is the development of the novel cancer therapy utilizing the α-Gal / anti-Gal antibody interaction: hyperacute rejection to tumor cell is induced by the labeling of tumor cell with α-Gal.
First, efficient synthesis of α-Gal epitope was achieved via one-pot glycosylation using imidate glycosyl donor and thioglycoside. Synthesized α-Gal was conjugated with anti-CD20 antibody, which is specifically recognize lymphoma cell. Cytotoxic assay using this antibody drug conjugate is under investigation. We also investigated the utilization of α-Gal as an adjuvant.
|
